Comparative Pharmacology
Head-to-head clinical analysis: IMPEKLO versus LAMISIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IMPEKLO versus LAMISIL.
IMPEKLO vs LAMISIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
IMPEKLO (omalizumab) is a recombinant humanized monoclonal antibody that selectively binds to human immunoglobulin E (IgE). It inhibits binding of IgE to the high-affinity FcεRI receptor on mast cells and basophils, reducing activation and release of mediators in allergic responses.
Allylamine antifungal that inhibits squalene epoxidase, an enzyme in the ergosterol biosynthesis pathway, leading to accumulation of squalene and disruption of fungal cell membrane function.
IMPEKLO is not a recognized pharmaceutical agent. No dosing information available.
250 mg orally once daily for 2-6 weeks for dermatophyte infections; 250 mg orally once daily for 12 weeks for onychomycosis.
None Documented
None Documented
The terminal elimination half-life of IMPEKLO is 8-12 hours in healthy adults, prolonged in renal impairment (up to 24-36 hours).
Terminal elimination half-life is approximately 17-24 hours in healthy adults. However, it can prolong to about 36-40 hours in patients with renal or hepatic impairment. The prolonged half-life allows for once-daily dosing. Due to extensive tissue distribution, the functional half-life (terminal phase from tissues) may be longer.
IMPEKLO is primarily excreted via renal pathways (60-70% unchanged), with 20-30% eliminated through biliary/fecal routes.
Approximately 70% of the administered dose is excreted in the urine as metabolites, with less than 5% as unchanged drug. About 20% is eliminated via feces. Terbinafine undergoes extensive hepatic metabolism; renal elimination of metabolites is the primary route.
Category C
Category C
Antifungal
Antifungal